These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1182 related articles for article (PubMed ID: 30514362)

  • 1. Tailored axillary surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer (TAXIS): study protocol for a multicenter, randomized phase-III trial.
    Henke G; Knauer M; Ribi K; Hayoz S; Gérard MA; Ruhstaller T; Zwahlen DR; Muenst S; Ackerknecht M; Hawle H; Fitzal F; Gnant M; Mátrai Z; Ballardini B; Gyr A; Kurzeder C; Weber WP
    Trials; 2018 Dec; 19(1):667. PubMed ID: 30514362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial.
    Krag DN; Anderson SJ; Julian TB; Brown AM; Harlow SP; Costantino JP; Ashikaga T; Weaver DL; Mamounas EP; Jalovec LM; Frazier TG; Noyes RD; Robidoux A; Scarth HM; Wolmark N
    Lancet Oncol; 2010 Oct; 11(10):927-33. PubMed ID: 20863759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eight-year follow up result of the OTOASOR trial: The Optimal Treatment Of the Axilla - Surgery Or Radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: A randomized, single centre, phase III, non-inferiority trial.
    Sávolt Á; Péley G; Polgár C; Udvarhelyi N; Rubovszky G; Kovács E; Győrffy B; Kásler M; Mátrai Z
    Eur J Surg Oncol; 2017 Apr; 43(4):672-679. PubMed ID: 28139362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Optimal treatment of the axilla after positive sentinel lymph node biopsy in early invasive breast cancer. Early results of the OTOASOR trial].
    Sávolt A; Musonda P; Mátrai Z; Polgár C; Rényi-Vámos F; Rubovszky G; Kovács E; Sinkovics I; Udvarhelyi N; Török K; Kásler M; Péley G
    Orv Hetil; 2013 Dec; 154(49):1934-42. PubMed ID: 24292111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of the Axilla in T1-2 Breast Cancer Patients with Macrometastatic Sentinel Node Involvement Who Underwent Breast-Conserving Therapy.
    Kuru B; Yuruker S; Sullu Y; Gursel B; Ozen N
    J Invest Surg; 2019 Jan; 32(1):48-54. PubMed ID: 28945489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tailored axillary surgery - A novel concept for clinically node positive breast cancer.
    Heidinger M; Knauer M; Tausch C; Weber WP
    Breast; 2023 Jun; 69():281-289. PubMed ID: 36922305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial.
    Giuliano AE; Ballman KV; McCall L; Beitsch PD; Brennan MB; Kelemen PR; Ollila DW; Hansen NM; Whitworth PW; Blumencranz PW; Leitch AM; Saha S; Hunt KK; Morrow M
    JAMA; 2017 Sep; 318(10):918-926. PubMed ID: 28898379
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial.
    Giuliano AE; Hunt KK; Ballman KV; Beitsch PD; Whitworth PW; Blumencranz PW; Leitch AM; Saha S; McCall LM; Morrow M
    JAMA; 2011 Feb; 305(6):569-75. PubMed ID: 21304082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Personalized axillary dissection: the number of excised lymph nodes of nodal-positive breast cancer patients has no significant impact on relapse-free and overall survival.
    Ebner F; Wöckel A; Janni W; Kreienberg R; Schwentner L; Wischnewsky M
    J Cancer Res Clin Oncol; 2017 Sep; 143(9):1823-1831. PubMed ID: 28439713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Imaging-Guided Localization on Performance of Tailored Axillary Surgery in Patients with Clinically Node-Positive Breast Cancer: Prospective Cohort Study Within TAXIS (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101).
    Weber WP; Heidinger M; Hayoz S; Matrai Z; Tausch C; Henke G; Zwahlen DR; Gruber G; Zimmermann F; Montagna G; Andreozzi M; Goldschmidt M; Schulz A; Mueller A; Ackerknecht M; Tampaki EC; Bjelic-Radisic V; Kurzeder C; Sávolt Á; Smanykó V; Hagen D; Müller DJ; Gnant M; Loibl S; Fitzal F; Markellou P; Bekes I; Egle D; Heil J; Knauer M
    Ann Surg Oncol; 2024 Jan; 31(1):344-355. PubMed ID: 37903951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Axillary lymph node treatment in breast cancer: an update.
    Williams PA; Suggs J; Mangana SH
    J Miss State Med Assoc; 2014 May; 55(5):145-7. PubMed ID: 25112128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is regional nodes radiotherapy an alternative to surgery?
    Offersen BV; Nielsen HM; Overgaard M; Overgaard J
    Breast; 2013 Aug; 22 Suppl 2():S118-28. PubMed ID: 24074772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Axillary treatment for operable primary breast cancer.
    Bromham N; Schmidt-Hansen M; Astin M; Hasler E; Reed MW
    Cochrane Database Syst Rev; 2017 Jan; 1(1):CD004561. PubMed ID: 28052186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Management of the axilla in breast cancer: evidences and unresolved issues].
    Fodor J; Polgár C; Péley G; Németh G
    Orv Hetil; 2001 Sep; 142(36):1941-50. PubMed ID: 11680099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trends in axillary treatment for breast cancer patients undergoing sentinel lymph node biopsy as determined by a questionnaire from the Japanese Breast Cancer Society.
    Imoto S; Yamauchi C; Komoike Y; Tsugawa K; Yotsumoto D; Wada N; Ueno T; Oba MS; Shien T; Sugae S; Tsuda H; Yoneyama K
    Breast Cancer; 2017 May; 24(3):427-432. PubMed ID: 27553957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival and axillary recurrence following sentinel node-positive breast cancer without completion axillary lymph node dissection: the randomized controlled SENOMAC trial.
    de Boniface J; Frisell J; Andersson Y; Bergkvist L; Ahlgren J; Rydén L; Olofsson Bagge R; Sund M; Johansson H; Lundstedt D;
    BMC Cancer; 2017 May; 17(1):379. PubMed ID: 28549453
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiation field design and regional control in sentinel lymph node-positive breast cancer patients with omission of axillary dissection.
    Setton J; Cody H; Tan L; Morrow M; Hudis C; Catalano J; McCormick B; Powell S; Ho A
    Cancer; 2012 Apr; 118(8):1994-2003. PubMed ID: 21882186
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Completion axillary lymph node dissection not required for regional control in patients with breast cancer who have micrometastases in a sentinel node.
    Yegiyants S; Romero LM; Haigh PI; DiFronzo LA
    Arch Surg; 2010 Jun; 145(6):564-9. PubMed ID: 20566977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Will we need lymph node dissection at all in the future?
    Bourez RL; Rutgers EJ; Van De Velde CJ
    Clin Breast Cancer; 2002 Dec; 3(5):315-22; discussion 323-5. PubMed ID: 12533260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial.
    Galimberti V; Cole BF; Viale G; Veronesi P; Vicini E; Intra M; Mazzarol G; Massarut S; Zgajnar J; Taffurelli M; Littlejohn D; Knauer M; Tondini C; Di Leo A; Colleoni M; Regan MM; Coates AS; Gelber RD; Goldhirsch A;
    Lancet Oncol; 2018 Oct; 19(10):1385-1393. PubMed ID: 30196031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 60.